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Advertisements impact the physiological efﬁcacy of
a branded drug
Emir Kamenicaa,1,2, Robert Nacleriob, and Anup Malanic,1
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Booth School of Business, bDepartment of Surgery, Pritzker School of Medicine, and cLaw School, University of Chicago, Chicago, IL 60637

advertising

| placebo effect

T

he medical literature on placebo effects suggests that beliefs
about the quality of a drug can impact the drug’s efﬁcacy.
Pharmaceutical companies spend $4.8 billion a year on direct-toconsumer advertisements in United States alone (1). Might these
advertisements impact consumers’ beliefs and thereby alter the
efﬁcacy of drugs?
We conducted two randomized clinical trials to measure the
impact of direct-to-consumer advertising on the objective, physiological effect of Claritin (Merck & Co.), a leading antihistamine
drug. A pilot study assessed the efﬁcacy of Claritin across subjects exposed to advertisements for Claritin, advertisements for
Zyrtec (McNeil), or control advertisements. At the outset of each
experiment, we gave each subject a skin test for common allergens, namely, grass, trees, mold, dust mites, ragweed, and cats.
Throughout the paper we refer to the subjects who had at least
one positive skin test as “subjects with allergies” and to the others
as “subjects without allergies.” Among subjects with allergies, the
efﬁcacy was the same across the three advertisement conditions, but among subjects without allergies, efﬁcacy was signiﬁcantly greater in the Claritin advertisements condition than in
the Zyrtec advertisements condition.
The heterogeneity of the treatment effect based on the allergy
status was discovered only ex post facto, so we conducted a followup trial to replicate these initial ﬁndings. To maximize statistical
power, the follow-up trial used a larger sample, assigned subjects
only to Claritin advertisements or Zyrtec advertisements, and
block-randomized subjects based on their allergy status. In addition, we elicited subjects’ beliefs about the efﬁcacy of Claritin
to examine whether any difference in impact of the advertisements
across the two subpopulations is driven by the relative malleability
of their beliefs.
We use the pilot study primarily as a source of a directional, ex
ante null hypothesis about the impact of the advertisements
within the two subpopulations. Our statistical analysis focuses on
the results from the follow-up trial. (Pooling the data from the
two trials only strengthens our main result.)
The follow-up trial proceeded as follows. A subject was given
a skin allergy test for common allergens. A research technician
administered a histamine challenge on the subject’s forearm, and
a baseline measurement of the wheal reaction was taken. The
wheal reaction is the slightly reddened, elevated area at the site
of the challenge and is a well-established measure of histamine
response (2). All normal individuals, whether they have allergies
www.pnas.org/cgi/doi/10.1073/pnas.1012818110

or not, develop a wheal reaction to a histamine challenge. The
subject reported her belief about the efﬁcacy of Claritin. She was
given 10 mg Claritin and was made aware that it was Claritin. She
was shown a movie spliced with naturally timed advertisement
breaks. In one condition (Claritin advertisements), one advertisement in each break was an advertisement for Claritin. In the
other condition (Zyrtec advertisements), one advertisement in
each break was an advertisement for Zyrtec. The Zyrtec advertisement stated that Zyrtec “starts working two hours faster
than Claritin.” The histamine challenge and wheal measurement
were repeated during the movie, 60 and 120 min after Claritin
was administered. At the end of the experiment, the subject was
again asked her belief about the efﬁcacy of Claritin.
We deﬁne the efﬁcacy of Claritin (at 60 and 120 min) as the
percentage decrease in the size of the wheal reaction relative to
the baseline. We thus have a subject-speciﬁc measure of efﬁcacy.
By comparing the efﬁcacy across the subjects in the two advertisement conditions, we identify the impact of advertisements on
the efﬁcacy of Claritin.
In the subpopulation without allergies, we ﬁnd that the efﬁcacy of Claritin at 120 min is substantially higher for subjects who
were exposed to Claritin advertisements. Claritin advertisements
have no signiﬁcant impact on efﬁcacy 60 min after the drug is
taken. This pattern is consistent with the observed changes in the
subjects’ beliefs. Exposure to Claritin advertisements in this subpopulation greatly increases the belief in the efﬁcacy of Claritin.
At the same time, the realized efﬁcacy of Claritin at 120 min (but
not at 60 min) is strongly correlated with the change in beliefs.
In the subpopulation with allergies, we ﬁnd no relationship
between exposure to Claritin advertisements and the change in
beliefs. Moreover, the advertisements have no impact on the
efﬁcacy of Claritin at 120 min. We do ﬁnd a curious negative
impact of Claritin advertisements on Claritin’s efﬁcacy at 60 min
in this subpopulation, but this effect cannot be mediated by the
(nonexistent) impact of advertisements on beliefs.
Overall, the results of the follow-up experiment support the
view that television advertisements can impact the physiological
efﬁcacy of a branded drug, at least in subpopulations of consumers whose beliefs about the drug’s efﬁcacy are sufﬁciently
malleable.
Beliefs about active drugs can inﬂuence their efﬁcacy (3, 4).
Moreover, placebo treatments disguised as pharmacologically
active treatments can have measurable physiological effects (5,
6). Hróbjartsson and Gøtzsche (7) examined 114 trials that had
both a placebo and a no-treatment arm and found that placebos
had a statistically signiﬁcant, positive effect on health outcomes
only in trials with continuous subjective outcomes, but their 95%
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IMMUNOLOGY

We conducted randomized clinical trials to examine the impact of
direct-to-consumer advertisements on the efﬁcacy of a branded
drug. We compared the objectively measured, physiological effect
of Claritin (Merck & Co.), a leading antihistamine medication,
across subjects randomized to watch a movie spliced with advertisements for Claritin or advertisements for Zyrtec (McNeil), a competitor antihistamine. Among subjects who test negative for
common allergies, exposure to Claritin advertisements rather than
Zyrtec advertisements increases the efﬁcacy of Claritin. We conclude that branded drugs can interact with exposure to
television advertisements.
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conﬁdence intervals admit the possibility of substantial positive
effects from placebos for all types of outcomes.
A small existing literature examines the impact of commercial
features of drugs on their efﬁcacy. Previous experiments show
that the color (8), the packaging (9), and the price (10) of drugs
affect their perceived efﬁcacy. Shiv et al. (11) examine the effects
of price and advertisements on puzzle-solving performance following consumption of an energy drink. However, they rely on
a behavioral outcome and use descriptive text rather than actual
advertisements for the drink. Studies that rely on self-reported or
behavioral outcomes might reﬂect only experimenter demand
effects. Other studies show that the price (12) and the brand (13,
14) of a beverage can affect brain activity during its consumption.
Our experiment used the short-term, objectively measured
physiological efﬁcacy of a drug to test placebo effects.
Economists have offered a variety of rationales for the enormous resources spent on advertising. Bagwell (15) categorizes
three basic views on why consumers respond to advertising. One
is that advertisements induce artiﬁcial product differentiation
and raise ﬁrm proﬁts at the expense of consumer welfare (16,
17). The second view is that advertising is informative (18–20).
Our inquiry relates most closely to the third view, which holds
that advertising is complementary to the consumption of a product
(21, 22). Becker and Murphy (22) consider a model in which exposure to advertising for product x (denoted by Ax ) enters a stable utility function Uðx; Ax Þ and increases the marginal utility of
x, i.e., ∂2 U=∂x∂Ax > 0. If drug advertisements generate placebo
effects, this fact would provide one mechanism through which
advertising and consumption are complements.
Results
Balancing Tests. The follow-up study enrolled 340 subjects. Table 1

shows the demographics of the subjects. By design, half of the
subjects had a positive skin test to at least one common allergen.
In both subpopulations (based on the allergy status), there are no
signiﬁcant differences across the advertisement conditions in the
age, sex, race, baseline wheal reaction, or initial belief about the
efﬁcacy of Claritin.
Overall Efﬁcacy of Claritin. Our main interest is not in the effect of

Claritin per se but rather in the way that this effect varies across
the advertisement conditions. Nonetheless, we report the overall
effect of Claritin to provide some context for our main results.

Claritin is quite effective in reducing the wheal reaction to
a histamine challenge. Recall that efﬁcacy (at 60 and 120 min) is
deﬁned as the percentage decrease in the size of the wheal reaction to the histamine challenge relative to the baseline. For
subjects without allergies, the average efﬁcacy is 12.51% at 60
min and 27.99% at 120 min. For subjects with allergies, the average efﬁcacy is 14.21% at 60 min and 28.43% at 120 min. Based
on a t test, at both 60 and 120 min there is no signiﬁcant difference in efﬁcacy across the two subpopulations (60 min: P =
0.514; 120 min: P = 0.863).
Impact of Advertisements on the Efﬁcacy of Claritin. Fig. 1 depicts
the efﬁcacy of Claritin at 60 and 120 min across the two advertisement conditions and the two subpopulations. Among subjects
without allergies, the efﬁcacy at 60 min was 10.83% in the Zyrtec
advertisements condition and 14.18% in the Claritin advertisements condition. This difference is not statistically signiﬁcant. At
120 min, however, the efﬁcacy in the Zyrtec advertisements condition was 25.00% compared with 30.97% in the Claritin advertisements condition. This difference of 5.97 percentage points is
statistically signiﬁcant (t test; one-sided P = 0.043). (Based on
our pilot study, we had a directional hypothesis for the followup experiment. Accordingly, we use a one-sided P value.) In the
subpopulation with allergies, the efﬁcacy at 60 min is signiﬁcantly
smaller in the Claritin advertisements condition than in the
Zyrtec advertisements condition; the difference at 120 min is
not signiﬁcant.
Mediation Through Change in Beliefs. The results in Fig. 1 are broadly
consistent with the observed changes in beliefs. Fig. 2 depicts
changes in beliefs across the two advertisement conditions and
the two subpopulations. Among subjects without allergies, those
who were exposed to Claritin advertisements increased their
belief in its efﬁcacy substantially more than those were exposed
to Zyrtec advertisements (t test; two-sided P = 0.004). Among
subjects with allergies, there were no signiﬁcant differences in
belief change across the two advertisement conditions (t test;
two-sided P = 0.577). This pattern buttresses the view that the
heterogeneous impact of the advertisements across the two subpopulations is driven by the differential malleability of their beliefs.
In Table 2 we report the correlation between belief change and
the realized efﬁcacy of Claritin. In both subpopulations, efﬁcacy
at 120 min (but not at 60 min) is signiﬁcantly correlated with
belief change. Thus, the curious negative impact of Claritin

Table 1. Baseline characteristics of subjects by allergy status and advertisement condition
Subpopulation characteristics
Subjects without allergies
Number of subjects
Age, y
Male, %
Black, %
Baseline wheal, mm2
Belief in efﬁcacy
Subjects with allergies
Number of subjects
Age, y
Male, %
Black, %
Baseline wheal, mm2
Belief in efﬁcacy

Claritin advertisements

Zyrtec advertisements

P value

85
27.25
31
28
21.72
5.55

85
26.40
31
26
21.61
5.42

0.65
1.00
0.73
0.96
0.26

83
27.83
48
35
21.18
5.43

87
29.30
41
40
21.50
5.14

0.11
0.37
0.48
0.58
0.28

Variable baseline wheal is the size of the wheal reaction to the baseline histamine challenge, administered
before Claritin. Belief in efﬁcacy is the subject’s initial answer to the question “On a scale of 1 to 7, where higher
numbers mean more effective, how effective do you think Claritin is in eliminating allergy symptoms?” P values
are based on a Wilcoxon rank-sum test comparing the subjects in the Claritin advertisements condition with the
subjects in the Zyrtec advertisements condition.
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Subjects with allergies
40

40

Subjects without allergies
Claritin ads

Claritin ads
Zyrtec ads

25
20
15

20
0

0

5

5

10

10

15

Efficacy

25

30

30

35

35

Zyrtec ads

0

60

0

120

60

120

Minutes after 10mg Claritin

Discussion
Our results suggest that a commercial phenomenon, television
advertising, may be an important trigger for psychologically

mediated physiological effects of a drug. Our ﬁndings also inform economic theories of advertising. They suggest that, at least
in the context of new consumers of pharmaceutical products,
advertisements can have a large impact on the efﬁcacy of a drug.
Our study has several limitations. First, it does not establish
whether, relative to a baseline of no advertisements, Claritin
advertisements improve Claritin efﬁcacy or Zyrtec advertisements reduce Claritin efﬁcacy. We eliminated the control group
(no drug advertisements) in the follow-up trial to increase statistical power, but we hope future research will shed light on
whether positive or negative advertisements have a greater effect. (In our pilot study, among subjects without allergies, Zyrtec

.8
.2

.4

.6
.4
0

0

.2

Change in belief

Subjects with allergies

.6

.8

Subjects without allergies

Claritin ads

Zyrtec ads

Claritin ads

Zyrtec ads

Ad condition

Fig. 2. Impact of advertisements on change in beliefs about Claritin by allergy status. Bars indicate mean change in belief. Whiskers indicate the SE of mean
change in belief.
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advertisements on efﬁcacy at 60 min among subjects with allergies cannot be mediated by belief change. (Advertisement
conditions did not change the beliefs in that subpopulation,
and belief change is uncorrelated with efﬁcacy at 60 min.)
However, the observed positive impact of Claritin advertisements on efﬁcacy at 120 min among subjects with allergies
might be mediated by the advertisements’ impact on the subjects’ beliefs.

ECONOMIC
SCIENCES

Fig. 1. Impact of advertising on the efﬁcacy of Claritin by allergy status. Solid and dotted lines indicate mean efﬁcacy. Whiskers indicate the SE of mean
efﬁcacy.

Table 2. Regression of Claritin efﬁcacy on self-reported beliefs
about efﬁcacy by allergy status

Subjects without allergies
Constant (SE)
Change in belief (SE)
Observations
R2
Subjects with allergies
Constant (SE)
Change in belief (SE)
Observations
R2

Efﬁcacy at 60 min

Efﬁcacy at 120 min

11.24 (2.23)
2.10 (1.63)
150
0.19

25.86 (1.95)
3.76 (1.43)
150
0.61

14.05 (1.82)
1.41 (1.40)
161
0.31

27.00 (1.95)
3.86 (1.50)
162
0.59

The table reports coefﬁcients from an ordinary least squares regression.
Twenty nonallergic subjects and eight allergic subjects said they did not have
beliefs about Claritin at baseline; they are coded as missing observations.
There also is one missing measurement of wheal reaction at 60 min,
accounting for the difference in the number of observations at 60 and
120 min among subjects with allergies.

advertisements reduced and Claritin advertisements increased
the efﬁcacy of Claritin relative to the control condition, but
neither effect was statistically signiﬁcant on its own.)
Second, our measure of drug efﬁcacy is difﬁcult to translate
into welfare. Consumers’ willingness to pay for antihistamines
presumably depends on the ability of those drugs to alleviate
allergy symptoms (such as a hay fever), but we have no way to
gauge whether a given percent reduction in the symptoms corresponds to a substantial economic magnitude.
Finally, our study does not identify the speciﬁc physiological
pathway through which advertisements modify the effect of
Claritin. We demonstrate that, among subjects without allergies,
advertisements alter subjects’ beliefs about the efﬁcacy of Claritin (Fig. 2), and we present evidence suggesting that these altered beliefs inﬂuence the efﬁcacy (Table 2). Our data, however,
do not speak to the physiological link between beliefs and efﬁcacy. One possible pathway is that pessimistic beliefs induced by
Zyrtec advertisements trigger stress in the subjects and that this
stress has a proinﬂammatory effect mediated by the production
of glucocorticoids by the hypothalamic–pituitary–adrenal axis or
catecholamines by the sympathetic nervous system (23). Identifying the pathway between beliefs and efﬁcacy would provide
guidance on whether our results would generalize to other types
of medications.
Our focus on the subjects without allergies somewhat diminishes the policy relevance of our ﬁndings. That said, our results
are likely to apply also to patients who were recently diagnosed
with allergies or to patients who are particularly susceptible to
advertisements. A recent study (24) reports that new users account for as many as 15% of all patients using antihistamines.
Although additional studies would be necessary to reach any
ﬁrm policy conclusions, our study raises a possibility that would
have important implications for regulation of drug advertisements. Pharmaceutical companies’ expenditure on direct-toconsumer advertising has grown more than 330% since 1996 and
has more than doubled as a percentage of total drug sales (1).
Government policy toward such advertising is heavily debated
(25). The United States and New Zealand are the only developed countries in the world that permit direct-to-consumer
advertising of prescription drugs, and the European Commission
is considering changes to its regulation of pharmaceutical advertising (26). A recent survey identiﬁed more than 2,800 articles
on the beneﬁts and costs of direct-to-consumer advertising of
drugs (27). Some of these studies claim that direct-to-consumer
advertising elevates demand for prescription drugs by inducing
patients to request advertised medications from their physicians
12934 | www.pnas.org/cgi/doi/10.1073/pnas.1012818110

(28). Our study suggests that advertising may have other important effects on public health. Speciﬁcally, television advertising may inﬂuence the efﬁcacy of a branded drug once it
is consumed.
Methods
Drug Choice. We used three criteria to identify a drug for our studies. The drug
had to be branded and advertised directly to consumers, so that real
advertisements could be used as stimuli. The drug also had to have objectively
measurable effects to rule out the possibility that advertisements affect only
the perception of effectiveness or the willingness of subjects to report what
they believe investigators want to hear. Finally, the drug had to be fast acting,
so that subjects’ behavior could be controlled for the duration of the experiment; otherwise, it is possible that advertisements might affect efﬁcacy
only indirectly, by modifying compliance or other behavior rather than by
altering the physiological consequences of the drug.
Antihistamine drugs ﬁt all these criteria. Histamine is an organic compound that is generated by mast cells when those cells are exposed to appropriate allergens. Histamines released by mast cells attach to H1 receptors
on the walls of blood vessels and thereby trigger vasodilation and increased
vascular permeability to allow transudation of ﬂuids. A consequence of this
vasodilation is local edema. Antihistamine drugs bind to the same receptors
as histamines, antagonizing their action on blood vessels. Therefore, antihistamine drugs reduce the histamine-induced edema of the skin.
People who have allergies release endogenous histamines when they are
exposed to an allergen. In our study, we injected people with histamines.
Individuals both with and without allergies develop a skin edema from
these exogenous histamines. Hence, we are able to study the effect of antihistamines in reducing the histamine-induced edema for all subjects and can
identify the impact of advertisements on efﬁcacy for subjects with and
without allergies.
We chose Claritin (loratadine), a leading antihistamine, as the drug for our
experiments. Claritin has been one of the most widely consumed drugs in the
United States, with annual sales reaching as high as $3 billion (29). It also is
one of the most widely advertised drugs in history; in 2000 alone, its maker,
Schering-Plough, spent $111 million advertising Claritin (30). Previous studies have shown that the number of prescriptions written for Claritin is correlated with advertising expenditure on Claritin (31).
Subjects. Our pilot study was conducted from July to October of 2008, and the
follow-up experiment was conducted from October 2011 to July 2012, both at
the University of Chicago Nasal Physiology Laboratory. The pilot study enrolled 150 subjects, and the follow-up study enrolled 340 subjects. In each
study, subjects were recruited through signs posted throughout the University. We enrolled healthy individuals of either sex between the ages of 18
and 65 y. We excluded individuals if they had consumed an antihistamine in
the previous 4 d; were pregnant or lactating; were of childbearing age and
were not using speciﬁc contraception; had had an upper respiratory infection
in the previous 14 d; had used any investigational agent in the last 30 d; were
using any medications that might affect skin testing for allergens; or had any
serious medical condition. We paid subjects $100 for participating in the pilot
study and $80 for participating in the follow-up experiment.
During the informed consent process, we told the subjects that the purpose
of the study was to examine the effect of Claritin. After subjects completed
all study procedures, we informed them that the study also examines the
impact of direct-to-consumer advertisements on the efﬁcacy of Claritin.
Protocol. The detailed procedure following the skin test differed between the
pilot study and the follow-up study. Because we focus on the results of the
follow-up study, we describe that protocol ﬁrst. Both studies were approved
by the Biological Science Division Institutional Review Board at the University
of Chicago.
Follow-up study. After the consent process, we gave each subject a skin test for
common allergens, namely, grass, trees, mold, dust mites, ragweed, and cats.
After the skin test, subjects were administered a histamine challenge. The
histamine challenge was a skin puncture that administered a percutaneous
dose of 6 mg/mL histamine base solution (10 mg/mL histamine dihydrochloride; Hollister-Stier Laboratories) to the forearm. Each subject had the
same arm used in every challenge. For some subjects it was the right arm and
for others the left arm. After each histamine challenge, a research technician
blinded to the subject’s condition measured the extent of the skin inﬂammation by tracing the wheal reaction. (In the pilot study, we also took
an additional measure of skin inﬂammation, the ﬂare. The ﬂare is a halo of
red, ﬂushed skin which surrounds the wheal. Measurement of ﬂare turned
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out to be very noisy, especially in patients with a dark skin tone. Accordingly,
we took only wheal measurements in the follow-up study.) One research
technician traced the outline of the wheal on a transparent tape which was
afﬁxed to the subject’s ﬁle. The subjects were told not to scratch the site of
the challenge. To ensure compliance, we measured their wheal reaction
shortly after each challenge and had the research technician monitor them
in the meantime. Of the 1,020 intended measurements, one measurement
was missed because the subject accidentally rubbed the tape and erased the
tracing. At the end of the study, another research technician, also blinded to
the subject’s condition, used ImageJ software to measure the traced area of
the wheal.
After the baseline challenge, subjects were asked whether they had
previously taken Claritin. After answering, subjects were given a 10-mg tablet
of Claritin to consume in front of the research technician. We presented the
tablet in its commercial packaging, so subjects were aware it was Claritin.
Subjects then were asked how effective they thought Claritin is at eliminating
allergy symptoms, on a scale of 1–7, with 7 meaning highly effective.
We then provided each subject with a portable DVD player with headphones and had subjects watch a movie (Shakespeare in Love). All subjects’
personal belongings, such as cell phones, iPods, and reading material, were
conﬁscated for the duration of the study (under the premise that we
needed to ensure a “controlled environment”). Consequently, all subjects
did watch the movie for the duration of the experiment. The movie was
spliced with naturally timed advertisement breaks (at roughly 6.5-min
intervals) as if edited for broadcast television. Each break was 90 s long and
contained multiple advertisements for automobiles and breakfast cereals.
We stratiﬁed the sample into subjects with and without a positive skin test
and block-randomized each subpopulation to two advertisement conditions:

Claritin advertisements and Zyrtec advertisements. One advertisement in
each commercial break was replaced with an advertisement for the designated product (Claritin or Zyrtec). Subjects saw the same version of the
designated product’s advertisement in each advertisement break. The advertisement used in the Zyrtec advertisements condition claimed, “Zyrtec’s
a lot faster. It starts working two hours faster than Claritin.”
Sixty and 120 min after subjects consumed Claritin, we repeated the
histamine challenge and the measurement of the wheal reaction. After the
ﬁnal histamine challenge, we again asked subjects to rate the efﬁcacy of
Claritin on a 1–7 scale.
Pilot study. The protocol for the pilot study differed from the follow-up experiment in several respects. First, the pilot study did not block-randomize
subjects based on their allergy status. Second, the pilot study assigned
subjects to three conditions rather than two. In addition to the Claritin
advertisements condition and Zyrtec advertisements condition, it included a
control condition in which advertisements for neither drug were shown. Moreover, in the Claritin advertisements and Zyrtec advertisements conditions,
subjects watched three versions of the designated product’s advertisements over the different breaks. Only one of the three Zyrtec advertisements mentioned Claritin. Third, in the pilot study we conducted the baseline
histamine challenge after the subject had begun watching the movie. Finally,
the pilot study did not elicit subjects’ beliefs about the efﬁcacy of Claritin.
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